z-logo
Premium
IMMUNE RESPONSIVENESS TO MYCOBACTERIUM LEPRAE OF HEALTHY HUMANS. APPLICATION OF THE LEUCOCYTE MIGRATION INHIBITION TEST
Author(s) -
Myrvang Bjørn
Publication year - 1974
Publication title -
acta pathologica microbiologica scandinavica section b microbiology and immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.909
H-Index - 88
eISSN - 1600-0463
pISSN - 0365-5563
DOI - 10.1111/j.1699-0463.1974.tb00239.x
Subject(s) - leprosy , mycobacterium leprae , immune system , immunology , medicine
Immune responsiveness to Mycobacterium leprae was studied, by the method of leucocyte migration inhibition, in ninety healthy adults allocated into four groups according to previous contact with leprosy patients. Groups working or living in close relationship with leprosy patients responded significantly more strongly to M. leprae than a group without such contact. With a selected concentration of M. leprae 71.2 per cent of medical attendants dealing with leprosy patients, 22.2 per cent of administrative staff of a leprosy hospital, and 50 per cent of household contacts of leprosy patients showed migration indices <0.800, but none of the group without known contact with leprosy patients showed indices below the threshold value. Since the inhibition of migration to BCG was similar in all groups, and no evidence was found that other mycobacteria had provoked the positive responses elicited by M. leprae , the above figures appear to represent individuals immunologically stimulated with M. leprae itself. The study therefore, showed that the method of leucocyte migration inhibition may be used as an assay for specific detection and enumeration of immune responses mounted by M. leprae. The results lend strong support to the view that leprosy bacilli are frequently transmitted from patients to contacts. The introduction of M. leprae into the human body is, however, rarely accompanied by development of clinical signs of leprosy.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here